Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

Rituximab 6fludarabine phosphate 3Vorinostat 3Specimen Handling 3Biopsy 3sargramostim 2ibrutinib 2binimetinib 2Sunitinib 2RFB4(dsFv)-PE38 recombinant immunotoxin 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2MK 2206 2Interferon-alpha 2Ifosfamide 2Flow Cytometry 2Etoposide 2Diphenhydramine 2Cladribine 2Carboplatin 2Bendamustine Hydrochloride 2B3(Fv)-PE38KDEL recombinant immunotoxin 2Analgesia 2Acetaminophen 2venetoclax 1veliparib 1tovorafenib 1tanespimycin 1obatoclax 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Hairy Cell × ON 01910 × Clear all
NCT00861510 2019-12-03

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡